Abstract

BackgroundImmune checkpoint inhibitors (ICIs) are highly effective in treating cancer; however, cardiotoxicity can occur, including myocarditis. Cardiac magnetic resonance (CMR) imaging is useful for evaluation of myocarditis, although it has not been well studied in ICI cardiotoxicity.MethodsWe identified patients referred for CMR evaluation of ICI cardiotoxicity from September 2015 through September 2019. We assessed structural and functional parameters, feature tracking (FT) left ventricular and atrial strain, T2- weighted ratios and quantitative late gadolinium enhancement (LGE). We also applied the Updated Lake Louise Criteria for diagnosis of myocarditis.ResultsOf the 20 patients referred, the median left ventricular ejection fraction (LVEF) was 52.5% ± 19.1 and 50% had a normal LVEF (≥53%). FT strain analysis revealed an average abnormal global longitudinal strain (GLS) of −9.8%± 4.2%. In patients with a normal LVEF, the average GLS remained depressed at −12.3%± 2.4%. In all patients, GLS demonstrated a significant negative correlation with LVEF (rs = −0.64, p 0.002). Sixteen patients (80%) had presence of LGE (14 non-ischemic pattern and 2 ischemic). Percent LGE did not correlate with any CMR parameters and notably did not correlate with LVEF (rs = −0.29, p = 0.22) or GLS (rs = 0.10, p = 0.67), highlighting the value of tissue characterization beyond functional assessment. Nine patients (45%) met full Updated Lake Louise Criteria and 85% met at least one criterion, suggestive of myocarditis in the correct clinical context. Thirteen patients (65%) were treated for ICI-associated myocarditis and, of these, 54% (n = 7) had recovery of LVEF to normal. There was no correlation between LVEF (p = 0.47), GLS (0.89), or % LGE (0.15) and recovery of LVEF with treatment.ConclusionIn patients with suspected ICI cardiotoxicity, CMR is an important diagnostic tool, even in the absence of overt left ventricular dysfunction, as abnormalities in left ventricular strain, T2 signal and LGE can identifying disease.

Highlights

  • Recent advances in immunotherapy have improved survival in cancer patients

  • Cardiac magnetic resonance (CMR) imaging is useful for evaluation of myocarditis, it has not been well studied in immune checkpoint inhibitors (ICIs) cardiotoxicity

  • We identified patients referred for CMR evaluation of ICI cardiotoxicity from September 2015 through September 2019

Read more

Summary

Introduction

Recent advances in immunotherapy have improved survival in cancer patients. The two FDAapproved classes of immune checkpoint inhibitors (ICIs) inhibit T-cell activation by targeting cytotoxic T lymphocyte antigen 4, programmed cell death protein-1 or programmed cell death ligand 1. The use of ICIs is limited by immune-related adverse events, including myocarditis [2]. There have been many case publications, cases series and a retrospective study of ICI cardiotoxicity, with a reported prevalence of up to 1.1% [3, 4]. Recent meta-analysis found that 9.8% of ICI treatment-related deaths were cardiovascular [5]. The incidence of major adverse cardiac events (MACE) in patients with ICI associated myocarditis has been reported as almost 50% [3]. Immune checkpoint inhibitors (ICIs) are highly effective in treating cancer; cardiotoxicity can occur, including myocarditis. Cardiac magnetic resonance (CMR) imaging is useful for evaluation of myocarditis, it has not been well studied in ICI cardiotoxicity

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call